Reaching Out to Improve Access to Radiation Therapy Treatment: Xstrahl attends regional conferences to meet with clinicians and discuss radiation therapy
FLASH Consortium Meets Prior to FRPT 2023
read more
Research Systems
Xstrahl to feature Radiant™ Aura at ASTRO 2023
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura, a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in San Diego, CA, October 1-3, 2023, booth #2216.
Antagonistic Effects of Ionising Radiation in Cell Competition
David Fernandez-Antoran PhD, Group Leader, The Gurdon Institute, University of Cambridge, Cambridge, UKARAID Researcher, Head of Cell Competition and Radiation Biology Laboratory, IIS-Aragon, Zaragoza, Spain Ionising radiation is one of the most common environmental...
Xstrahl & SmART Scientific Solutions to showcase two new software solutions for radiation research at ICRR in Montréal, Canada
Xstrahl & SmART Scientific Solutions to showcase two new software solutions for radiation research at ICRR in Montréal, Canada
Xstrahl will demonstrate SmART-RAD and SmART-Contour at the 17th International Congress for Radiation Research (ICRR) August 27-30
kV Radiotherapy Treatment in Locally Advanced or Metastatic Breast Cancer
Researchers sought to understand the role of kV treatment in locally advanced and/or metastatic breast cancer in which kV radiotherapy was used as the primary modality or as supportive treatment to linac-based RT to gain local tumor control and improve the patient’s quality of life. See details of the recent study, Kilovoltage radiotherapy as a supportive treatment in locally advanced or metastatic breast cancer – a series of six case reports, and the full report on six cases.
Xstrahl Delivers CIX FLASH, the First Commercial X-Ray Based Preclinical FLASH Irradiator
Xstrahl Delivers CIX FLASH, the First Commercial X-Ray Based Preclinical FLASH Irradiator CIX FLASH supports translational research into current and expanded FLASH radiotherapy techniques Xstrahl announced today the first delivery of CIX FLASH, the world’s first...
Evaluation of Radiation Therapy of Ocular Tumours
Xstrahl in Action A recent study investigated reduced risk of damage to nearby organs during the treatment of ocular tumours. using our Small Animal Radiation Research Platform (SARRP). Publication Orthovoltage X-ray Minibeam Radiation Therapy for the Treatment of...
SARRP Used in Salivary Gland Radiation Research
In the recent study, Short-term and bystander effects of radiation on murine submandibular glands, researchers sought to understand hyposalivation effects that can be caused by radiation. See details below and the full study here.
CIX3 used in HER2-positive Tumor Research
See what researchers found in the recent study: Enhancement of antitumor immune response by radiation therapy combined with dual immune checkpoint inhibitor in a metastatic model of HER2‑positive murine tumor. See the original publication here.
Contact Us